 |
 |
Amorcyte, Inc. is a therapeutics company pursuing cell-based therapies for cardiovascular diseases.
Amorcyte's primary product, AMR-001 is an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction (AMI). |
|
|
|
|
|
|
|
|
 |
AMORCYTE COMPLETES PHASE I TRIAL OF STEM CELL THERAPY FOR ACUTE MYOCARDIAL INFARCTION
(Amorcyte) announced today the completion of the phase I clinical trial of its lead product, AMR-001.
HACKENSACK, New Jersey - (April 1, 2008)
AMORCYTE CARDIAC CELL THERAPY TRIAL COMPLETES SECOND OF FOUR PHASES
Stem cell therapy trial picks up pace with three sites now accruing patients
Hackensack, New Jersey - May 8, 2007
AMORCYTE CARDIAC CELL THERAPY TRIAL PASSES FIRST STAGE AND OPENS TWO NEW SITES
Stem cell therapy trial proceeds to next stage and opens in two new clinical centers
Hackensack, New Jersey - January 2, 2007
AMORCYTE SECURES ADDITIONAL FUNDING TO EXPAND CLINICAL PROGRAM IN CARDIOVASCULAR THERAPY
PA Early Stage joins Colt Ventures in expanding Amorcyte’s product program
Hackensack, New Jersey (PRWEB) October 23, 2006
|
|
